JP7227964B2 - 黒色腫の検出方法 - Google Patents

黒色腫の検出方法 Download PDF

Info

Publication number
JP7227964B2
JP7227964B2 JP2020516379A JP2020516379A JP7227964B2 JP 7227964 B2 JP7227964 B2 JP 7227964B2 JP 2020516379 A JP2020516379 A JP 2020516379A JP 2020516379 A JP2020516379 A JP 2020516379A JP 7227964 B2 JP7227964 B2 JP 7227964B2
Authority
JP
Japan
Prior art keywords
hla
cflar
melanoma
expression level
loc646471
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524524A5 (https=
JP2020524524A (ja
Inventor
モドリン アービン
キッド マーク
ドロズドフ イグナート
Original Assignee
リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー filed Critical リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー
Publication of JP2020524524A publication Critical patent/JP2020524524A/ja
Publication of JP2020524524A5 publication Critical patent/JP2020524524A5/ja
Application granted granted Critical
Publication of JP7227964B2 publication Critical patent/JP7227964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
JP2020516379A 2017-05-25 2018-05-21 黒色腫の検出方法 Active JP7227964B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511058P 2017-05-25 2017-05-25
US62/511,058 2017-05-25
PCT/US2018/033658 WO2018217627A1 (en) 2017-05-25 2018-05-21 Methods for melanoma detection

Publications (3)

Publication Number Publication Date
JP2020524524A JP2020524524A (ja) 2020-08-20
JP2020524524A5 JP2020524524A5 (https=) 2021-07-26
JP7227964B2 true JP7227964B2 (ja) 2023-02-22

Family

ID=62620988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020516379A Active JP7227964B2 (ja) 2017-05-25 2018-05-21 黒色腫の検出方法

Country Status (14)

Country Link
US (2) US20180340934A1 (https=)
EP (1) EP3631017B1 (https=)
JP (1) JP7227964B2 (https=)
KR (1) KR102763004B1 (https=)
CN (1) CN111315897B (https=)
AU (1) AU2018273844B2 (https=)
BR (1) BR112019024481A2 (https=)
CA (1) CA3064732A1 (https=)
DK (1) DK3631017T3 (https=)
ES (1) ES2920288T3 (https=)
IL (1) IL270787B2 (https=)
MX (1) MX2019014026A (https=)
PL (1) PL3631017T3 (https=)
WO (1) WO2018217627A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102763004B1 (ko) 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113360A1 (en) 2006-09-07 2008-05-15 Riker Adam I Melanoma Gene Signature
JP2010508826A (ja) 2006-11-03 2010-03-25 ベイラー リサーチ インスティテュート 血中白血球マイクロアレイ分析を介した、転移性メラノーマの診断及び免疫抑制インディケーターのモニタリング
US20100248225A1 (en) 2006-11-06 2010-09-30 Bankaitis-Davis Danute M Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2016044330A1 (en) 2014-09-15 2016-03-24 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838732A4 (en) * 2005-01-07 2010-07-14 Univ Johns Hopkins BIOMARKER FOR MELANOME
EP2488874A4 (en) * 2009-10-13 2013-08-14 Univ Johns Hopkins BIOMARKERS FOR THE IDENTIFICATION OF MELANOMOTUM CELLS
EA201590041A1 (ru) * 2012-07-03 2015-04-30 Ратиофарм Гмбх Твердая форма холиновой соли вемурафениба
KR102763004B1 (ko) 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113360A1 (en) 2006-09-07 2008-05-15 Riker Adam I Melanoma Gene Signature
JP2010508826A (ja) 2006-11-03 2010-03-25 ベイラー リサーチ インスティテュート 血中白血球マイクロアレイ分析を介した、転移性メラノーマの診断及び免疫抑制インディケーターのモニタリング
US20100248225A1 (en) 2006-11-06 2010-09-30 Bankaitis-Davis Danute M Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2016044330A1 (en) 2014-09-15 2016-03-24 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Also Published As

Publication number Publication date
EP3631017B1 (en) 2022-03-23
CN111315897A (zh) 2020-06-19
IL270787B2 (en) 2023-08-01
CN111315897B (zh) 2024-10-22
ES2920288T3 (es) 2022-08-02
US12399179B2 (en) 2025-08-26
JP2020524524A (ja) 2020-08-20
AU2018273844A1 (en) 2019-12-19
EP3631017A1 (en) 2020-04-08
CA3064732A1 (en) 2018-11-29
BR112019024481A2 (pt) 2020-07-14
MX2019014026A (es) 2020-08-03
US20230022236A1 (en) 2023-01-26
AU2018273844B2 (en) 2024-11-14
US20180340934A1 (en) 2018-11-29
KR102763004B1 (ko) 2025-02-04
WO2018217627A1 (en) 2018-11-29
KR20200030034A (ko) 2020-03-19
PL3631017T3 (pl) 2022-09-26
DK3631017T3 (da) 2022-06-20
IL270787B1 (en) 2023-04-01
IL270787A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
KR101437718B1 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
US7998674B2 (en) Gene expression profiling for identification of prognostic subclasses in nasopharyngeal carcinomas
AU2017341084A1 (en) Classification and prognosis of cancer
MX2013013746A (es) Biomarcadores para cancer de pulmon.
US20190062843A1 (en) Micro-rna biomarkers and methods of using same
KR20180009762A (ko) 폐암을 진단하거나 검출하기 위한 방법 및 조성물
CA2961725C (en) A method of predicting risk of recurrence of cancer
JP2017521058A (ja) 癌処置のための個別化三剤治療を選択するための方法
JP6931926B2 (ja) 遺伝子発現プロファイル及び乳癌におけるその使用
AU2015264422A1 (en) Centromere/kinetochore protein genes for cancer diagnosis, prognosis and treatment selection
JP2024523848A (ja) 癌検出方法、キットおよびシステム
US20260071281A1 (en) Gene signatures for predicting metastasis of melanoma and patient prognosis
WO2020175903A1 (ko) 간암 재발 예측용 dna 메틸화 마커 및 이의 용도
BR112016005225B1 (pt) Métodos para avaliar câncer de mama em um indivíduo
WO2016118670A1 (en) Multigene expression assay for patient stratification in resected colorectal liver metastases
JP7223741B2 (ja) 形質細胞疾患の検出方法
JP7227964B2 (ja) 黒色腫の検出方法
US10059998B2 (en) Microrna signature as an indicator of the risk of early recurrence in patients with breast cancer
AU2009337963B2 (en) Prognosis of breast cancer patients by monitoring the expression of two genes
US20250051848A1 (en) High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data
HK40017741A (en) Methods for melanoma detection
HK40017741B (en) Methods for melanoma detection
HK40046957A (en) Gene signatures for predicting metastasis of melanoma and patient prognosis
HK40046957B (en) Gene signatures for predicting metastasis of melanoma and patient prognosis
HK40030202B (en) Methods for detection of plasma cell dyscrasia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230210

R150 Certificate of patent or registration of utility model

Ref document number: 7227964

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250